Posted by Michael Wonder on 17 Jul 2024
ICER releases draft evidence report on treatments for transthyretin amyloid cardiomyopathy
17 July 2024 - Public comment period now open until 13 August 2024; requests to make oral comment during public meeting also being accepted.
The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of acoramidis (BridgeBio Pharma), tafamidis (Vyndamax/Vyndaqel, Pfizer) and vutrisiran (Amvuttra, Alnylam Pharmaceuticals) for the treatment of transthyretin amyloid cardiomyopathy.
